Evaluation of Aminobutyric Acid, Glutamic Acid, Calcium, Thiamine, Pyridoxine and Cyanocobalamin as Therapy for Vertigo

Sponsor
Fundação Educacional Serra dos Órgãos (Other)
Overall Status
Recruiting
CT.gov ID
NCT05221892
Collaborator
(none)
334
1
2
13.2
25.2

Study Details

Study Description

Brief Summary

The goal of this clinical trial is to assess the efficacy and safety of a combination of aminobutyric acid, glutamic acid, calcium, thiamine, pyridoxine and cyanocobalamin as adjuvant therapy for vertigo comparatively to ginger under a double-blind randomized study design.

Condition or Disease Intervention/Treatment Phase
  • Drug: Gamma-aminobutyric acid tartarate, glutamic acid, dibasic calcium phosphate, thiamine nitrate, pyridoxine chloride and cyanocobalamin
  • Drug: Ginger
Phase 4

Detailed Description

Motion sickness is a chronic condition characterized by vestibular changes in response to stimuli caused either by movement or movement perception triggered by car, train, ship or aircraft transportation, amusement park rides, virtual reality and simulators, walking, exercising, as well as under the absence of gravity in space.The studied combination drug is composed by GABA (gamma-aminobutyric acid), the main inhibitory neurotransmitter of the central nervous system. The former lowers anxiety symptoms. Its precursor, glutamic acid, is the amino acid found in greater concentration under free form in the CNS; it is closely related to brain metabolism and, in contrast to GABA, it is the main excitatory neurotransmitter; glutamic acid also has anxyolytic therapeutic properties. Thiamine or vitamin B1 is a cofactor in the synthesis of acetylcholine, which plays a central role in the initiation and propagation of neural impulse in the CNS as well as it does in the skeletal and myocardial muscles. Pyridoxine or vitamin B6 plays a role in the synthesis of neurotransmitters such as dopamine as well as in the metabolism of tryptophan, resulting in an increase in serotonin so providing well-being and anxiety relief. Pyridoxine is essential for the proper functioning of the CNS (including at nausea and vomiting center). Cyancobalamin or Vitamin B12 plays a role in the growth and repair of nerve fibers. Importantly it also improves blood flow in the brain, with secondary vertigo improvement. The combined use of these substances provides relief of vertigo due to motion sickness. Zingiber officinale is a species of the Zingiberacaea family, widely used in traditional and herbal medicine for the treatment of various clinical conditions such as vertigo.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
334 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Care Provider, Investigator)
Primary Purpose:
Treatment
Official Title:
Double Blind Evaluation of Gamma-aminobutyric Acid Tartarate 100 mg, Glutamic Acid 100 mg, Dibasic Calcium Phosphate 50 mg, Thiamine Nitrate 25 mg, Pyridoxine Chloride 10 mg and Cyanocobalamin 5 mcg Versus Ginger for Vertigo-kinetosis
Actual Study Start Date :
Nov 22, 2021
Anticipated Primary Completion Date :
Sep 30, 2022
Anticipated Study Completion Date :
Dec 30, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Test combination

Gamma-aminobutyric acid tartrate 100mg, glutamic acid 100mg, dibasic calcium phosphate 50mg, thiamine nitrate 25mg, pyridoxine hydrochloride 10mg and cyanocobalamin 5mcg

Drug: Gamma-aminobutyric acid tartarate, glutamic acid, dibasic calcium phosphate, thiamine nitrate, pyridoxine chloride and cyanocobalamin
Tablets to be taken 30 minutes before each of 4 trips.
Other Names:
  • Gamma-aminobutyric acid tartarate, and combinations
  • Active Comparator: Comparative medication

    Ginger extract 160mg (8mg gingerols)

    Drug: Ginger
    Tablets to be taken 30 minutes before each of 4 trips.
    Other Names:
  • Zingiber officinale
  • Outcome Measures

    Primary Outcome Measures

    1. motion sickness assessment questionnaire [1 year]

      The MSAQ consists of 16 questions, answered on a scale from one to nine points, which assesses the gastrointestinal, central and peripheral nervous system and soporous symptoms related to motion sickness.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 65 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • clinical kinetosis

    • female study subjects must agree in using contraceptives during study period

    • dated informed consent read, understood and undersigned

    Exclusion Criteria:
    • hypersensitivity to the drugs of the study

    • history of gallblader stones

    • history of gastric mucosa inflammation

    • arterial blood pressure >145/100 mmHg

    • use of medication for kinetosis other than the study drugs

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Centro Universitário Serra dos Órgãos - UNIFESO Teresópolis RJ Brazil 25964004

    Sponsors and Collaborators

    • Fundação Educacional Serra dos Órgãos

    Investigators

    • Principal Investigator: carlos p nunes, MD, Fundação Educacional Serra dos Órgãos

    Study Documents (Full-Text)

    More Information

    Publications

    Responsible Party:
    Carlos Pereira Nunes, professor, Fundação Educacional Serra dos Órgãos
    ClinicalTrials.gov Identifier:
    NCT05221892
    Other Study ID Numbers:
    • 50635421.30000.5247
    First Posted:
    Feb 3, 2022
    Last Update Posted:
    Feb 3, 2022
    Last Verified:
    Jan 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Carlos Pereira Nunes, professor, Fundação Educacional Serra dos Órgãos
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 3, 2022